San Francisco -- Bridge Pharmaceuticals, a San Francisco-based provider of pre-clinical contract pharmaceutical, biologics and vaccine development services, said on Tuesday that it has secured $35 million in its second round of funding. New investor Granite Global Ventures joined the company's previous investors in the round, which the company plans to use to expand its preclinical operations in China. The capital also will help the company pay for its December acquisition of Maryland-based Gene Logic's Preclinical Division, as well as for a planned construction project in Beijing.
http://www.bridgecro.com/
http://biz.yahoo.com/bw/070213/20070213005583.html?.v=1
Listings
Notices
Recent Posts
- San Jose-Based Adobe Systems Acquires Behance
- Santa Clara-Based Coherent Acquires Germany's Lumera Laser
- Gangnam Style Becomes First Video to Hit 1 Billion Views on YouTube
- Redwood Shores-Based Oracle to Acquire Eloqua for $871 Million
- Palo Alto-Based Pluribus Networks Raises $23 Million in Third Round
- Foxconn Acquires $200 Million Stake in San Mateo-Based GoPro
- Palo Alto-Based LUMO BodyTech Raises $5 Million in First Round
- Palo Alto-Based Signifyd Lands $2 Million in Seed Funding
- San Francisco-Based FitStar Raises $1M for Health and Fitness Platform
- National Geographic Suspending New Posts on Instagram
Editor: Rich Scherr
For news tips and editorial issues,
contact editor Rich Scherr at
rich@techwiremedia.com
For advertising information, contract
Parul Nath at parul@techwiremedia.com
A Service of Tech Wire Media
Archives
- December 16, 2012 - December 22, 2012
- December 9, 2012 - December 15, 2012
- December 2, 2012 - December 8, 2012
- November 25, 2012 - December 1, 2012
- November 18, 2012 - November 24, 2012
- November 11, 2012 - November 17, 2012
- November 4, 2012 - November 10, 2012
- October 28, 2012 - November 3, 2012
- October 21, 2012 - October 27, 2012
- October 14, 2012 - October 20, 2012
